Key PointsAI has boosted Shopify’s recent financial results, and there remains a large untapped market.

2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution

(RTTNews) - DexCom Inc. (DXCM) reported earnings for third quarter of $275.1 million

DexCom Inc. Q3 Sales Increase 

(RTTNews) - DexCom, Inc. (DXCM) announced that its Dexcom G7 15 Day continuous glucose monitoring (CGM) system will be available in Canada beginning in November for adults aged 18 and older living with diabetes.

Dexcom To Launch G7 15 Day CGM System In Canada In November; Stock Up 

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #9 analyst pick, moving up by 19 spots.
        
This rank is formed by averaging the analyst opinions for each component from each br

S&P 500 Analyst Moves: DXCM

Fintel reports that on October 7, 2026, Barclays initiated coverage of DexCom (NASDAQGS:DXCM) (WBAG:DXCM) with a Overweight recommendation.This initiation follows a prior action by Barclays on May 18, 2026, when the firm maintained an Underweight rating on the stock. DexCom, Inc.

Barclays Initiates Coverage of DexCom with Overweight Rating

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc. News